Muscarine chloride

  • (+)-Muscarine chloride
  • L-(+)-Muscarine chloride
  • (+)-Tetrahydro-4b-hydroxy-N,N,N,5a-tetramethyl-2a-furanmethanaminium chloride
  • (+)-(2S,4R,5S)-Tetrahydro-4-hydroxy-N,N,N,5-tetramethyl-2-furanmethanammonium chloride
Formula
C9H20NO2.Cl
Structure
Description
White powder. Extremely hygroscopic.
Uses
Prototype muscarinic acetylcholine receptor agonist; active enantiomer.

Registry Numbers and Inventories.
CAS
2303-35-7
EC (EINECS/ELINCS)
218-963-2
26/27/28
22 36/37/39 45
RTECS
QG3500000
RTECS class
Drug
UN (DOT)
2811
Beilstein/Gmelin
4723996
Beilstein Reference
6-18

Properties.
Formula
C9H20NO2.Cl
Formula mass
209.75
Melting point, °C
180 - 181
Solubility in water
Very soluble

Hazards and Protection.
Protection
Compatible chemical-resistant gloves. Chemical safety goggles.
Respirators
Government approved respirator.
Small spills/leaks
Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete.
Stability
Stable at normal temperatures and pressures.
Decomposition
Carbon monoxide, Carbon dioxide, Nitrogen oxides.

Fire.
Fire fighting
Extinguish using Carbon dioxide, dry chemical powder, or appropriate foam. Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.
Fire potential
Non-combustible, substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes.
Hazards
Contact with metals may evolve flammable hydrogen gas.
Combustion products
Fire may produce irritating, corrosive and/or toxic gases.

Health.
Exposure effects
Onset is within 30 to 120 minutes. Symptoms are similar to cholinergic poisoning, including excessive perspiration, salivation and lacrimation, bradycardia miosis, blurred vision, abdominal pain, diarrhea hypotension and pulmonary congestion. This condition is often referred to as the PSL syndrome (perspiration salivation, lacrimation). Profuse sweating is the most useful clinical finding to distinguish between this group and general gastrointestinal irritant mushrooms Symptoms are usually short-lived, subsiding within two hours without treatment, but can persist 6 to 24 hours.
   Ingestion
Excessive salivation, abdominal cramps, and vomiting followed by watery diarrhea are common findings.
   Inhalation
Bronchospasm, wheezing, nasal discharge, and bronchorrhea may occur.
   Skin
Contact with molten substance may cause severe burns to skin and eyes. See Inhalation.
   Eyes
See Inhalation.

First aid
 
   Ingestion
Administer charcoal as a slurry (240 mL water/30 g charcoal). Usual dose: 25 to 100 g in adults/adolescents, 25 to 50 g in children (1 to 12 years), and 1 g/kg in infants less than 1 year old. Atropine should be administered if life-threatening cholinergic symptoms exist. A test dose of 1-2 mg intravenously is standard in an adult while 0.02 mg/kg is given in children. Poisoned patients will show no signs of atropinism and the atropine may be repeated as is necessary. End point of therapy is cessation of secretions, not just mydriasis.
   Inhalation
If inhaled, remove to fresh air. If breathing becomes difficult, call a physician.
   Skin
In case of skin contact, flush with copious amounts of water for at least 15 minutes. Remove contaminated clothing and shoes. Call a physician.
   Eyes
In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician.

Transport.
UN number
2811
Response guide
Hazard class
6.1
Packing Group
II